Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5% (Lotemax_BMT)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Bausch & Lomb Incorporated
Information provided by (Responsible Party):
Shahzad Mian, University of Michigan
ClinicalTrials.gov Identifier:
NCT01695668
First received: September 25, 2012
Last updated: September 27, 2012
Last verified: September 2012
  Purpose

The purpose of this research is to:

  1. Evaluate the safety and efficacy of a steroid eye drop (Lotemax) in patients who have been diagnosed with graft-versus-host disease (GVHD), which is a complication that may occur after bone marrow transplant where the newly transplanted material attacks the patient's body and may cause eye dryness.
  2. Assess the safety and efficacy of Lotemax in decreasing the eye's reaction to the process in GVHD before the patient undergoes bone marrow transplant.
  3. Compare how well Lotemax works in decreasing the process in GVHD with an immunosuppressive eye drop (Restasis), which has been commonly used in the treatment of this condition.

Condition Intervention
Dry Eyes
Drug: Lotemax
Drug: Restasis

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol

Resource links provided by NLM:


Further study details as provided by University of Michigan:

Primary Outcome Measures:
  • Ocular GVHD [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: August 2011
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lotemax
Loteprednol Etabonate 0.5%
Drug: Lotemax
Active Comparator: Restasis
Cyclosporine
Drug: Restasis

Detailed Description:

Allogeneic bone marrow or peripheral stem cell transplantation result in Graft-versus-Host disease. Ocular symptoms may be the first presentation of GVHD and may be seen in the absence of systemic manifestations. GVHD is categorized into acute and chronic forms as defined by 100 days after the transplant. Acute GVHD is characterized by dermatitis, hepatitis, and enteritis. Chronic GVHD involves the skin, mouth, liver, gastrointestinal tract, lungs, and eyes. Ocular GVHD is a common cause of dry eye symptoms in patients who have undergone bone marrow transplant (BMT), and can be defined as ocular surface disease in the context of GVHD. Dry eyes develop in 76% of acute GVHD patients and between 62.5% and 81.8% of chronic GVHD patients. Current treatment for ocular GVHD includes topical cyclosporine 0.05% (Restasis, Allergan). Topical loteprednol etabonate 0.5% (Lotemax, Bausch and Lomb) has been shown to be safe and efficacious in treatment of inflammatory ocular disorders, but has not been prospectively studied in ocular GVHD.

2. Hypothesis: We anticipate that topical loteprednol etabonate 0.5% will be safe and efficacious in treatment of ocular GVHD patients, and would add to the armamentarium of therapeutics for this disease. Further, by following the natural progression of the disease prior to a patient's Bone Marrow Transplant (BMT), we may elucidate a new standard of care for these patients - one that involves referral to an ophthalmologist before ocular GVHD symptoms arise.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Scheduled for allogenic bone marrow transplant

Exclusion Criteria:

Allergic reaction to loteprednol or cyclosporine, previous allogenic transplant

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01695668

Sponsors and Collaborators
University of Michigan
Bausch & Lomb Incorporated
Investigators
Principal Investigator: Shahzad Mian, MD University of Michigan
  More Information

No publications provided

Responsible Party: Shahzad Mian, Terry J. Bergstrom Professor for Resident Education, Associate Professor, Cornea and External Disease, University of Michigan
ClinicalTrials.gov Identifier: NCT01695668     History of Changes
Other Study ID Numbers: Lotemax_00045815
Study First Received: September 25, 2012
Last Updated: September 27, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of Michigan:
Graft versus Host Disease (GVHD)
dry eyes
Bone marrow transplant (BMT)
Restasis
Lotemax

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Graft vs Host Disease
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases
Immune System Diseases
Cyclosporins
Cyclosporine
Loteprednol etabonate
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Therapeutic Uses
Dermatologic Agents
Antirheumatic Agents
Anti-Allergic Agents

ClinicalTrials.gov processed this record on July 22, 2014